Efficacy Evaluation of Tissue Plasminogen Activator with Anti-Vascular Endothelial Growth Factor Drugs for Submacular Hemorrhage Treatment: A Meta-Analysis
Submacular hemorrhage (SMH) is the accumulation of blood in the macular area that can severely damage the macular structure and visual function. Recently, the intraocular administration of tissue plasminogen activator (TPA) with anti-vascular endothelial growth factor (anti-VEGF) drugs was reported...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-01-01
|
| Series: | Journal of Clinical Medicine |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2077-0383/12/3/1035 |
| _version_ | 1797624048674406400 |
|---|---|
| author | Xuejun He Wenye Cao Zhiyi Wang Ningzhi Zhang Kexin Xu Lu Yu Yiqiao Xing Ning Yang |
| author_facet | Xuejun He Wenye Cao Zhiyi Wang Ningzhi Zhang Kexin Xu Lu Yu Yiqiao Xing Ning Yang |
| author_sort | Xuejun He |
| collection | DOAJ |
| description | Submacular hemorrhage (SMH) is the accumulation of blood in the macular area that can severely damage the macular structure and visual function. Recently, the intraocular administration of tissue plasminogen activator (TPA) with anti-vascular endothelial growth factor (anti-VEGF) drugs was reported to have a positive effect on SMH. This meta-analysis aimed to explore the efficacy and safety of the drug combination. We systematically searched the Web of Science, MEDLINE, EMBASE, and Cochrane Library databases and screened relevant full-length literature reports. The quality of the reports was assessed by two independent reviewers. The best-corrected visual acuity (BCVA) and foveal thickness (FT) were considered the main indicators of efficacy. RevMan 5.4 software was used for this meta-analysis. Twelve studies were analyzed, and the results showed that BCVA at 1 month (<i>p</i> < 0.001), 3 months (<i>p</i> < 0.001), 6 months (<i>p</i> < 0.001), and the last follow-up (<i>p</i> < 0.001) was improved relative to the preoperative value. The postoperative FT was lower than the preoperative FT (<i>p</i> < 0.001). No significant difference in efficacy was observed between subretinal and intravitreal TPA injections (<i>p</i> = 0.37). TPA with anti-VEGF drugs is safe for SMH treatment and can significantly improve BCVA and reduce FT. |
| first_indexed | 2024-03-11T09:37:51Z |
| format | Article |
| id | doaj.art-52ef6cbd16a742f1a6e3be496be23466 |
| institution | Directory Open Access Journal |
| issn | 2077-0383 |
| language | English |
| last_indexed | 2024-03-11T09:37:51Z |
| publishDate | 2023-01-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Journal of Clinical Medicine |
| spelling | doaj.art-52ef6cbd16a742f1a6e3be496be234662023-11-16T17:10:45ZengMDPI AGJournal of Clinical Medicine2077-03832023-01-01123103510.3390/jcm12031035Efficacy Evaluation of Tissue Plasminogen Activator with Anti-Vascular Endothelial Growth Factor Drugs for Submacular Hemorrhage Treatment: A Meta-AnalysisXuejun He0Wenye Cao1Zhiyi Wang2Ningzhi Zhang3Kexin Xu4Lu Yu5Yiqiao Xing6Ning Yang7Eye Center, Renmin Hospital of Wuhan University, 238 Jiefang Road, Wuhan 430060, ChinaEye Center, Renmin Hospital of Wuhan University, 238 Jiefang Road, Wuhan 430060, ChinaEye Center, Renmin Hospital of Wuhan University, 238 Jiefang Road, Wuhan 430060, ChinaEye Center, Renmin Hospital of Wuhan University, 238 Jiefang Road, Wuhan 430060, ChinaEye Center, Renmin Hospital of Wuhan University, 238 Jiefang Road, Wuhan 430060, ChinaEye Center, Renmin Hospital of Wuhan University, 238 Jiefang Road, Wuhan 430060, ChinaEye Center, Renmin Hospital of Wuhan University, 238 Jiefang Road, Wuhan 430060, ChinaEye Center, Renmin Hospital of Wuhan University, 238 Jiefang Road, Wuhan 430060, ChinaSubmacular hemorrhage (SMH) is the accumulation of blood in the macular area that can severely damage the macular structure and visual function. Recently, the intraocular administration of tissue plasminogen activator (TPA) with anti-vascular endothelial growth factor (anti-VEGF) drugs was reported to have a positive effect on SMH. This meta-analysis aimed to explore the efficacy and safety of the drug combination. We systematically searched the Web of Science, MEDLINE, EMBASE, and Cochrane Library databases and screened relevant full-length literature reports. The quality of the reports was assessed by two independent reviewers. The best-corrected visual acuity (BCVA) and foveal thickness (FT) were considered the main indicators of efficacy. RevMan 5.4 software was used for this meta-analysis. Twelve studies were analyzed, and the results showed that BCVA at 1 month (<i>p</i> < 0.001), 3 months (<i>p</i> < 0.001), 6 months (<i>p</i> < 0.001), and the last follow-up (<i>p</i> < 0.001) was improved relative to the preoperative value. The postoperative FT was lower than the preoperative FT (<i>p</i> < 0.001). No significant difference in efficacy was observed between subretinal and intravitreal TPA injections (<i>p</i> = 0.37). TPA with anti-VEGF drugs is safe for SMH treatment and can significantly improve BCVA and reduce FT.https://www.mdpi.com/2077-0383/12/3/1035submacular hemorrhagetissue plasminogen activatoranti-vascular endothelial growth factorcombination treatmentmeta-analysis |
| spellingShingle | Xuejun He Wenye Cao Zhiyi Wang Ningzhi Zhang Kexin Xu Lu Yu Yiqiao Xing Ning Yang Efficacy Evaluation of Tissue Plasminogen Activator with Anti-Vascular Endothelial Growth Factor Drugs for Submacular Hemorrhage Treatment: A Meta-Analysis Journal of Clinical Medicine submacular hemorrhage tissue plasminogen activator anti-vascular endothelial growth factor combination treatment meta-analysis |
| title | Efficacy Evaluation of Tissue Plasminogen Activator with Anti-Vascular Endothelial Growth Factor Drugs for Submacular Hemorrhage Treatment: A Meta-Analysis |
| title_full | Efficacy Evaluation of Tissue Plasminogen Activator with Anti-Vascular Endothelial Growth Factor Drugs for Submacular Hemorrhage Treatment: A Meta-Analysis |
| title_fullStr | Efficacy Evaluation of Tissue Plasminogen Activator with Anti-Vascular Endothelial Growth Factor Drugs for Submacular Hemorrhage Treatment: A Meta-Analysis |
| title_full_unstemmed | Efficacy Evaluation of Tissue Plasminogen Activator with Anti-Vascular Endothelial Growth Factor Drugs for Submacular Hemorrhage Treatment: A Meta-Analysis |
| title_short | Efficacy Evaluation of Tissue Plasminogen Activator with Anti-Vascular Endothelial Growth Factor Drugs for Submacular Hemorrhage Treatment: A Meta-Analysis |
| title_sort | efficacy evaluation of tissue plasminogen activator with anti vascular endothelial growth factor drugs for submacular hemorrhage treatment a meta analysis |
| topic | submacular hemorrhage tissue plasminogen activator anti-vascular endothelial growth factor combination treatment meta-analysis |
| url | https://www.mdpi.com/2077-0383/12/3/1035 |
| work_keys_str_mv | AT xuejunhe efficacyevaluationoftissueplasminogenactivatorwithantivascularendothelialgrowthfactordrugsforsubmacularhemorrhagetreatmentametaanalysis AT wenyecao efficacyevaluationoftissueplasminogenactivatorwithantivascularendothelialgrowthfactordrugsforsubmacularhemorrhagetreatmentametaanalysis AT zhiyiwang efficacyevaluationoftissueplasminogenactivatorwithantivascularendothelialgrowthfactordrugsforsubmacularhemorrhagetreatmentametaanalysis AT ningzhizhang efficacyevaluationoftissueplasminogenactivatorwithantivascularendothelialgrowthfactordrugsforsubmacularhemorrhagetreatmentametaanalysis AT kexinxu efficacyevaluationoftissueplasminogenactivatorwithantivascularendothelialgrowthfactordrugsforsubmacularhemorrhagetreatmentametaanalysis AT luyu efficacyevaluationoftissueplasminogenactivatorwithantivascularendothelialgrowthfactordrugsforsubmacularhemorrhagetreatmentametaanalysis AT yiqiaoxing efficacyevaluationoftissueplasminogenactivatorwithantivascularendothelialgrowthfactordrugsforsubmacularhemorrhagetreatmentametaanalysis AT ningyang efficacyevaluationoftissueplasminogenactivatorwithantivascularendothelialgrowthfactordrugsforsubmacularhemorrhagetreatmentametaanalysis |